Spots Global Cancer Trial Database for cd47
Every month we try and update this database with for cd47 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | NCT04675294 | Head and Neck C... Head and Neck S... | evorpacept pembrolizumab | 18 Years - | ALX Oncology Inc. | |
| Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors | NCT04980690 | Advanced Malign... | IBC0966 | 18 Years - 75 Years | SUNHO（China）BioPharmaceutical CO., Ltd. | |
| A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors | NCT05892718 | Advanced Solid ... Refractory Non-... | HCB101 | 18 Years - | FBD Biologics Limited | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | NCT05737628 | Lymphoma | BYON4228 + Ritu... | 18 Years - | Byondis B.V. | |
| Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT04445701 | Multiple Myelom... | AO-176 AO-176 + Dex AO-176 + Dex + ... | 18 Years - | Arch Oncology | |
| Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors | NCT04980690 | Advanced Malign... | IBC0966 | 18 Years - 75 Years | SUNHO（China）BioPharmaceutical CO., Ltd. | |
| A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy | NCT05276310 | Advanced Cancer | IMC-002 | 19 Years - | ImmuneOncia Therapeutics Inc. | |
| A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors | NCT05765851 | Advanced Solid ... Breast Cancer | DS-1103a T-DXd | 18 Years - | Daiichi Sankyo | |
| A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | NCT05167409 | Microsatellite ... | Evorpacept (ALX... Cetuximab Pembrolizumab | 18 Years - | University of Colorado, Denver | |
| A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196 | Hematologic Neo... | CC-90002 Rituximab | 18 Years - | Celgene | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology | |
| Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies | NCT03248479 | Hematological M... | Magrolimab Azacitidine | 18 Years - | Gilead Sciences | |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | NCT05002127 | Gastric Cancer Gastroesophagea... Gastric Adenoca... | Evorpacept (ALX... Trastuzumab Ramucirumab Paclitaxel | 18 Years - | ALX Oncology Inc. | |
| AO-176 in Multiple Solid Tumor Malignancies | NCT03834948 | Solid Tumor | AO-176 AO-176 + Paclit... AO-176 + Pembro... | 18 Years - | Arch Oncology | |
| A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | NCT04755244 | Acute Myeloid L... AML, Adult | evorpacept venetoclax azacitidine | 18 Years - | ALX Oncology Inc. | |
| Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT04445701 | Multiple Myelom... | AO-176 AO-176 + Dex AO-176 + Dex + ... | 18 Years - | Arch Oncology | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology | |
| A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | NCT04755244 | Acute Myeloid L... AML, Adult | evorpacept venetoclax azacitidine | 18 Years - | ALX Oncology Inc. | |
| A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196 | Hematologic Neo... | CC-90002 Rituximab | 18 Years - | Celgene | |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | NCT05675449 | Multiple Myelom... | Elranatamab Carfilzomib Maplirpacept | 18 Years - | Pfizer | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | NCT05737628 | Lymphoma | BYON4228 + Ritu... | 18 Years - | Byondis B.V. | |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | NCT05675449 | Multiple Myelom... | Elranatamab Carfilzomib Maplirpacept | 18 Years - | Pfizer | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology | |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT05626322 | Diffuse Large B... | Maplirpacept Tafasitamab Lenalidomide | 18 Years - | Pfizer | |
| Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT04445701 | Multiple Myelom... | AO-176 AO-176 + Dex AO-176 + Dex + ... | 18 Years - | Arch Oncology | |
| Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | NCT04599634 | Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Chronic Lymphoc... B-Cell Lymphoma | Obinutuzumab Venetoclax Magrolimab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT05626322 | Diffuse Large B... | Maplirpacept Tafasitamab Lenalidomide | 18 Years - | Pfizer | |
| A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas | NCT04306224 | Solid Tumor Lymphoma | IMC-002 | 18 Years - | ImmuneOncia Therapeutics Inc. | |
| A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) | NCT04417517 | Higher Risk Mye... | evorpacept azacitidine | 18 Years - | ALX Oncology Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
